Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.52 |
| ▸ | HDAC3 known ✓ | O15379 | 1/20 | 0.43 |
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 known ✓ | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 1/20 | 0.43 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.41 |
| ▸ | PDE4D known ✓ | Q08499 | 1/20 | 0.41 |
| ▸ | MGAM | O43451 | 1/20 | 0.52 |
| ▸ | SI | P14410 | 1/20 | 0.52 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.48 |
| ▸ | KDM6B | O15054 | 1/20 | 0.48 |
| ▸ | KDM5C | P41229 | 1/20 | 0.48 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.48 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 5/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Succinic Acid Diethyl Ester SCHEMBL27966388 | 0.97 | MGAM (0.55) | MGAMGAASIMGAM2CYP1A2 | |
| SCHEMBL363334 | 0.97 | MGAM (0.55) | MGAMGAASIMGAM2CYP1A2 | |
| Succinic Acid Diethyl Ester SCHEMBL27830938 | 0.97 | MGAM (0.55) | MGAMGAASIMGAM2CYP1A2 | |
| SCHEMBL262913 | 0.97 | MGAM (0.55) | MGAMGAASIMGAM2CYP1A2 | |
| Methyl Alcohol SCHEMBL6759312 | 0.95 | MGAM (0.52) | MGAMGAASIMGAM2CYP1A2 | |
| Water SCHEMBL1110192 | 0.95 | MGAM (0.52) | MGAMGAASIMGAM2CYP1A2 | |
| SCHEMBL10784546 | 0.95 | MGAM (0.52) | MGAMGAASIMGAM2CYP1A2 | |
| Bromide SCHEMBL15666439 | 0.95 | MGAM (0.52) | MGAMGAASIMGAM2CYP1A2 | |
| Methyl Alcohol SCHEMBL2707570 | 0.95 | MGAM (0.52) | MGAMGAASIMGAM2CYP1A2 | |
| SCHEMBL5014278 | 0.95 | MGAM (0.52) | MGAMGAASIMGAM2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9221862-B2 | Erythromycin ethylsuccinate crystalline hydrate, preparation and uses thereof | LIU LI (CN) | 2015-12-29 | — | — | US | claimed |
| US-20140128583-A1 | ERYTHROMYCIN ETHYLSUCCINATE CRYSTALLINE HYDRATE, PREPARATION AND USES THEREOF | LIU LI (CN) | 2014-05-08 | — | — | US | claimed |
| CN-1824647-B | Crystal of (+-)2-(dimethylamino)-1-{[o-(m-methoxyphenethyl)phenoxy]methyl}ethyl hydrogen succinate hydrochloride | MITSUBISHI PHARMA CORP | 2011-04-20 | — | — | CN | claimed |
| CN-1824647-A | Crystal of (+-)2-(dimethylamino)-1-{[o-(m-methoxyphenethyl)phenoxy]methyl}ethyl hydrogen succinate hydrochloride | MITSUBISHI PHARMA CORP (JP) | 2006-08-30 | — | — | CN | claimed |
| CN-116813556-A | Sulfadimidine neuraminidase inhibitor as well as preparation method and application thereof | 上海应用技术大学 | 2023-09-29 | — | — | CN | disclosed |
| CN-114644635-B | Triazole tricyclic derivative and preparation method and application thereof | 上海济煜医药科技有限公司 | 2023-02-03 | — | — | CN | disclosed |
| US-11548910-B2 | Oligonucleotide production method | NISSAN CHEMICAL CORPORATION (JP) | 2023-01-10 | — | — | US | disclosed |
| CN-108186623-B | Application of emodin succinyl ester compound in preparation of hypolipidemic drugs | 江苏康缘药业股份有限公司 | 2022-12-23 | — | — | CN | disclosed |
| CN-115280147-A | UV excitable polyfluorene-based conjugates and their use in analyte detection methods | 阿特生物探索公司 | 2022-11-01 | — | — | CN | disclosed |
| WO-2022143617-A1 | NAGILACTONE COMPOUND AND USE THEREOF IN PREPARATION OF ANTI-TUMOR DRUG | 中国科学院上海药物研究所 | 2022-07-07 | — | — | WO | disclosed |
| WO-2022135335-A1 | TRIAZOLE TRICYCLIC DERIVATIVE AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海济煜医药科技有限公司 | 2022-06-30 | — | — | WO | disclosed |
| CN-114394960-A | Dibenzocyclooctyne-tetraethylene glycol-active ester compound, preparation method and application | 宜昌博仁凯润药业有限公司 | 2022-04-26 | — | — | CN | disclosed |
| EP-0638071-B1 | HETEROCYCLIC CARBONIC ACID DERIVATIVES WHICH BIND TO RETINOID RECEPTORS (RAR) | EISAI CO LTD (JP) | 1997-04-09 | — | — | EP | disclosed |
| US-5612356-A | RETINOID ANTAGONISTS | EISAI CO., LTD. (JP) | 1997-03-18 | — | — | US | disclosed |
| EP-0638071-A1 | HETEROCYCLIC CARBONIC ACID DERIVATIVES WHICH BIND TO RETINOID RECEPTORS (RAR). | EISAI CO LTD (JP) | 1995-02-15 | — | — | EP | disclosed |
| WO-1994014777-A1 | HETEROCYCLIC CARBONIC ACID DERIVATIVES WHICH BIND TO RETINOID RECEPTORS (RAR) | EISAI CO., LTD. (JP) | 1994-07-07 | — | — | WO | disclosed |
| US-4948809-A | TREATMENT OF AILMENTS DUE TO THROMBOCYTE AGGREGATION OR KIDNEY DYSFUNCTION | BOEHRINGER MANNHEIM GMBH (DE) | 1990-08-14 | — | — | US | disclosed |
| US-4925845-A | HYPOTENSIVE AGENTS | BOEHRINGER MANNHEIM GMBH (DE) | 1990-05-15 | — | — | US | disclosed |
| US-3998802-A | POLYAMIDES, CELLULOSE ESTERS, POLYESTERS, POLYACRYLONITRILES | BASF AKTIENGESELLSCHAFT (DT) | 1976-12-21 | — | — | US | disclosed |
| US-3997589-A | ANTIPHLOGISTIC, ANTIPROLIFERATIVES | BOEHRINGER INGELHEIM GMBH (DT) | 1976-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11548910-B2 | Oligonucleotide production method | RNGTT, OSGEP, PHAX | GAA 1813/4885HDAC3 2020/4885HDAC1 3843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.